Formulation of new generation drug delivery system for dry powder inhalation.
Based on the formulation method the dry powder inhalers (DPIs) can be divided in too types: carrier-based and carrier-free drug delivery systems. The newest researches report about several high potency carrier-free formulations, where the active ingredient and the excipients are together formulated to the DPI form. However, in Hungary the commercially available DPIs are carrier-based (e.g. lactose), which means that only the mic-onized active ingredient reaches the deeper lungs, the big carrier deposits in the upper airways. The present work is about formulating a high efficacy mannitol-based Pulmonary Drug Delivery System (PDDS), which is able to delivery different types of active ingredients to the deeper lungs with higher deposition rate. The present study involves the physico-chemical and aerodynamical characterisation of mannitol-based PDDS. The results demonstrated the use of the appropriate excipients (leucine, poly-vinyl-alcohol, cyclodextrine) and solvent combination (ethanol-water) during the co-spray drying, increases the inhalation properties of the mannitol. Such carrier systems with optimized properties can increase the aerolization efficacy of the active ingredient.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:86 |
|---|---|
| Enthalten in: |
Acta pharmaceutica Hungarica - 86(2016), 3 vom: 22., Seite 75-83 |
| Sprache: |
Ungarisch |
|---|
| Weiterer Titel: |
Not available |
|---|
| Beteiligte Personen: |
Chvatal, A [VerfasserIn] |
|---|
| Themen: |
3OWL53L36A |
|---|
| Anmerkungen: |
Date Completed 02.04.2018 Date Revised 02.04.2018 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM281469334 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM281469334 | ||
| 003 | DE-627 | ||
| 005 | 20231225031717.0 | ||
| 007 | tu | ||
| 008 | 231225s2016 xx ||||| 00| ||hun c | ||
| 028 | 5 | 2 | |a pubmed24n0938.xml |
| 035 | |a (DE-627)NLM281469334 | ||
| 035 | |a (NLM)29489079 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a hun | ||
| 100 | 1 | |a Chvatal, A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Formulation of new generation drug delivery system for dry powder inhalation. |
| 246 | 3 | 3 | |a Not available |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 02.04.2018 | ||
| 500 | |a Date Revised 02.04.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Based on the formulation method the dry powder inhalers (DPIs) can be divided in too types: carrier-based and carrier-free drug delivery systems. The newest researches report about several high potency carrier-free formulations, where the active ingredient and the excipients are together formulated to the DPI form. However, in Hungary the commercially available DPIs are carrier-based (e.g. lactose), which means that only the mic-onized active ingredient reaches the deeper lungs, the big carrier deposits in the upper airways. The present work is about formulating a high efficacy mannitol-based Pulmonary Drug Delivery System (PDDS), which is able to delivery different types of active ingredients to the deeper lungs with higher deposition rate. The present study involves the physico-chemical and aerodynamical characterisation of mannitol-based PDDS. The results demonstrated the use of the appropriate excipients (leucine, poly-vinyl-alcohol, cyclodextrine) and solvent combination (ethanol-water) during the co-spray drying, increases the inhalation properties of the mannitol. Such carrier systems with optimized properties can increase the aerolization efficacy of the active ingredient | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 650 | 7 | |a Excipients |2 NLM | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 650 | 7 | |a Mannitol |2 NLM | |
| 650 | 7 | |a 3OWL53L36A |2 NLM | |
| 700 | 1 | |a Szabo, B |e verfasserin |4 aut | |
| 700 | 1 | |a Szabo-Revesz, P |e verfasserin |4 aut | |
| 700 | 1 | |a Ambrus, R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta pharmaceutica Hungarica |d 1965 |g 86(2016), 3 vom: 22., Seite 75-83 |w (DE-627)NLM000024872 |x 0001-6659 |7 nnns |
| 773 | 1 | 8 | |g volume:86 |g year:2016 |g number:3 |g day:22 |g pages:75-83 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 86 |j 2016 |e 3 |b 22 |h 75-83 | ||